Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 1
2000 2
2001 4
2002 1
2003 5
2004 3
2005 2
2006 3
2007 4
2008 1
2009 4
2010 5
2011 8
2012 11
2013 7
2014 7
2015 12
2016 12
2017 12
2018 9
2019 8
2020 7
2021 11
2022 5
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for kathy months
Search for Kathy Montes instead (2 results)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL; PALLAS groups and investigators. Gnant M, et al. J Clin Oncol. 2022 Jan 20;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 7. J Clin Oncol. 2022. PMID: 34874182 Free PMC article. Clinical Trial.
At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results b …
At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who …
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Sallman DA, et al. J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449813 Free PMC article. Clinical Trial.

Responding patients had significant reductions in TP53 variant allele frequency and p53 expression by immunohistochemistry, with 21 (38%) achieving complete molecular remission (variant allele frequency < 5%). Median overall survival was 10.8 months with significant imp

…
Responding patients had significant reductions in TP53 variant allele frequency and p53 expression by immunohistochemistry, with 21 (38%) ac …
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA. Kornblum N, et al. J Clin Oncol. 2018 Jun 1;36(16):1556-1563. doi: 10.1200/JCO.2017.76.9331. Epub 2018 Apr 17. J Clin Oncol. 2018. PMID: 29664714 Free PMC article. Clinical Trial.
The study was designed to have 90% power to detect a 70% improvement in median progression-free survival from 5.4 months to 9.2 months. Secondary end points included objective response and clinical benefit rate (response or stable disease for at least 24 weeks). ... …
The study was designed to have 90% power to detect a 70% improvement in median progression-free survival from 5.4 months to 9.2 mo …
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.
Baisley K, Kemp TJ, Kreimer AR, Basu P, Changalucha J, Hildesheim A, Porras C, Whitworth H, Herrero R, Lacey CJ, Schiller JT, Lucas E, Mutani P, Dillner J, Indangasi J, Muwonge R, Hayes RJ, Pinto LA, Watson-Jones D. Baisley K, et al. Lancet Glob Health. 2022 Oct;10(10):e1485-e1493. doi: 10.1016/S2214-109X(22)00306-0. Lancet Glob Health. 2022. PMID: 36113532 Free PMC article. Clinical Trial.
For this immunobridging analysis, the primary objective was to compare geometric mean concentrations (GMCs) at 24 months after one dose in the per-protocol population compared with in historical cohorts: the one-dose 2-valent vaccine group in DoRIS was compared with recipi …
For this immunobridging analysis, the primary objective was to compare geometric mean concentrations (GMCs) at 24 months after one do …
Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial.
Gonsalves N, Doerfler B, Zalewski A, Yang GY, Martin LJ, Zhang X, Shoda T, Brusilovsky M, Aceves S, Thompson K, Rudman Spergel AK, Furuta G, Rothenberg ME, Hirano I. Gonsalves N, et al. J Allergy Clin Immunol. 2023 Sep;152(3):676-688. doi: 10.1016/j.jaci.2023.05.024. Epub 2023 Jul 18. J Allergy Clin Immunol. 2023. PMID: 37462600
METHODS: Adults aged 18 to 65 years with histologically active EoG/EoGE (30 eosinophils per high-power field) in the stomach and/or duodenum and gastrointestinal symptoms within the month preceding enrollment were prospectively enrolled onto a single-arm clinical trial to …
METHODS: Adults aged 18 to 65 years with histologically active EoG/EoGE (30 eosinophils per high-power field) in the stomach and/or duodenum …
Best practices of formal new graduate nurse transition programs: an integrative review.
Rush KL, Adamack M, Gordon J, Lilly M, Janke R. Rush KL, et al. Int J Nurs Stud. 2013 Mar;50(3):345-56. doi: 10.1016/j.ijnurstu.2012.06.009. Epub 2012 Jul 12. Int J Nurs Stud. 2013. PMID: 22795800 Review.
The stronger evidence suggests that new graduate education should focus on practical skill development, preceptors should receive a level of formal training, formal support should be available at least through the difficult six to nine month post-hire period, opportunities …
The stronger evidence suggests that new graduate education should focus on practical skill development, preceptors should receive a level of …
Vestibular and balance treatment of the concussed athlete.
Aligene K, Lin E. Aligene K, et al. NeuroRehabilitation. 2013;32(3):543-53. doi: 10.3233/NRE-130876. NeuroRehabilitation. 2013. PMID: 23648608 Review.
Persistence of symptoms beyond initial impact may require medication trials or adjustments that are tailored to the patient's medical history and/or neurocognitive rehabilitative techniques such as vestibular rehabilitation therapy to prevent progression of neurologic sequelae. P …
Persistence of symptoms beyond initial impact may require medication trials or adjustments that are tailored to the patient's medical histor …
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Traina TA, et al. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373071 Free PMC article. Clinical Trial.
CBR at 16 weeks was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup. Median progression-free survival was 2.9 months (95% CI, 1.9 to 3.7 months) in the ITT population and 3.3 months (95% CI, 1.9 to 4.1 …
CBR at 16 weeks was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup. Median progressio …
Kathy Pan, sticks and pummelling: techniques used to induce abortion by Burmese women on the Thai border.
Belton S, Whittaker A. Belton S, et al. Soc Sci Med. 2007 Oct;65(7):1512-23. doi: 10.1016/j.socscimed.2007.05.046. Epub 2007 Jul 2. Soc Sci Med. 2007. PMID: 17604893
This ethnographic study used various methods to collect data over 10 months in Tak Province, Thailand. The authors describe the women's motives and means of ending their pregnancies and some of the difficulties in obtaining reliable modern methods of contraception. ...
This ethnographic study used various methods to collect data over 10 months in Tak Province, Thailand. The authors describe the women …
144 results